The QUALITY project has been promoted by GFB Odv www.lgmd2e.org. GFB have been dealing with Limb girdle muscular distrophy types 2C/R5-2D/R3-2E/R4 (alfa, beta and gamma sarcoglicanopathy) for 11 years and with the specific scientific research. The president and founder is Beatrice Vola.
As far as 2010 the Limb girdle muscular distrophy (LGMD) was considered a neglected pathology, this means that there was no scientific research on the disease. There were no specific organizations for this disease and clinical studies on patients were very few.
There is currently only one research project for LGMD2E or LGMDR4, based on gene therapy and, at the moment, the first clinical trial on patients is underway, by Sarepta Therapeutics. You can see the trial structure on clinicaltrials.gov at the following link:
https://clinicaltrials.gov/ct2/show/NCT03652259?cond=lgmd2e&draw=2&rank=2
There are no registries for LGMD2E or LGMDR4 and other forms of LGMD2D or LGMDR3 and 2C or LGMDR5. Other gene therapy studies on LGMD2D or LGMDR3 and 2C or LGMDR5 are ongoing and very soon clinical trials phase 1 will start. You can find further information on GFB site at the following link:
http://www.beta-sarcoglicanopathy.org/scientific-research.html
At present, GFB is the only existing organization dealing with LGMD2E or LGMDR4. For the last 11 years, GFB have been concerned in looking for other families affected by this disease and, nowadays, we are in contact with more than 600 patients, all over the world and belonging to different groups. We strongly believe that together we can do more!
GFB would be to start the Quality project to better define the data collected in the past years.
The QUALITY Project is promoted by GFB organization to structure international patients data collected in past years, study the patients' quality of life and encourage the participation of patients in natural history studies and clinical trials.
In the questionnaire you’ll find questions related to the following subject areas:
The questions will be semi-structured with the prevailing multiple-choice type.
There is the possibility to give a funding to the centers that will take part in the project.
All the data will be collected with the patients’ informed consent . The data will be processed for statistical porposes and published on a scientific magazine. In the article, all the associations and the clinical centers taking part to the survey will be mentioned among the authors.
The project is fully funded by GFB.
GFB attended the
GFB attended the
June 14th 2021
GFB: a project for LGMD quality of life studies
©2020 GFBONLUS.IT - GRUPPO FAMILIARI BETA-SARCOGLICANOPATIE
+39 328 0075986 This email address is being protected from spambots. You need JavaScript enabled to view it.
Via Civasca 112 23018 Talamona - SO Italia
Made by Betsoft